About Event


Given the excitement and anticipation of increasingly more promising prophylactic treatments and gene therapy, the inaugural Hemophilia Drug Development Summit plays host to the leading pharma and biotech players working to develop longer acting and more efficacious therapies to overcome significant unmet medical need and prevent resistance to factor replacement therapies.

Fueled by current investment in the space and novel therapeutic strategies to improve current standard of care,  the development of hemophilia therapeutics has been reinvigorated. Touted as an area of large unmet medical need but a well understood and defined disease profile, investment in this space is set to grow.

Attend the inaugural Hemophilia Drug Development Summit to identify novel drug development strategies’ from therapeutic antibodies through to gene therapies and bring life-changing treatments to patients in need.

Attending this industry driven forum will enable you to:

  • Harness new understanding of the biological and long term impacts of these novel therapies
  • Optimize your clinical trial design to save time and costs
  • Define suitable endpoints so that the benefits of your therapy are clear and apparent

"Great Conference. The agenda was very focused & stayed within the defined scope."

Past Attendee at the Gene Therapy for Rare Disorders Summit: TrackCel

"I really enjoyed the broad spectrum of topics that the conference covered & the networking opportunities."

Past Attendee at the Gene Therapy for Rare Disorders Summit: Sanofi

"This was a well-balanced mix of speakers representing early & late drug development efforts, sharing both approaches that have worked and ones that have failed. We often only hear the success stories, but one can learn maybe even more from the failures. "

Past Attendee at the Complement-Based Drug Development Summit: Ablynx NV